NASDAQ: MDGL

Madrigal Pharmaceuticals (MDGL) Stock Analysis & Forecast

Nov 13 close

$427.39+2.18 (+0.5%)

Gekko Brief

AI summaryNov 9 close

This week's news is dominated by a wave of securities-law investigation announcements from multiple law firms, including Kaplan Fox, SBS Law, and Kessler Topaz Meltzer & Check, following a whistleblower complaint alleging that Madrigal suppressed adverse liver-injury findings and presented unreproducible efficacy data for Rezdiffra. The complaint concerns the safety and efficacy data underlying the drug. Separately, Madrigal's Q3 2026 results, reported 3 November, showed net sales of $431 million, up 50% year-over-year, with year-to-date sales crossing $1 billion and annualizing at over $1.7 billion, while active Rezdiffra patients reached 55,850 versus 29,500 a year earlier.

MDGL closed at $432.79, up 8.3% on the day but down 8.3% over one month and 19.1% over three months, sitting below both its 50-day ($484.73) and 200-day ($497.36) averages. The GekkoIndex reads 69.2, placing the stock in the Accumulation zone, while the price sits 42.7% below Gekko Fair Value of $754.69.

Earnings are not due until 18 February 2027, 100 days out, keeping that catalyst outside a typical 20-day hold. Smart money activity over the last 90 days shows 5 insider purchases alongside an insider sale by General Counsel Kelley and a Form 4 filing from Baker Bros. Advisors; unusual options activity in the last 30 days shows 1 signal, with put premium of $666,520 against call premium of $398,090. Seasonality from this point has averaged +10.5% over 20 trading days across 5 years, rising in 3 of them.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Madrigal Pharmaceuticals price vs fair value

▲$813.11$427.39Nov ’25May ’26Nov ’26
Close $427.39200-day averageGekko Fair Value $813.11

Madrigal Pharmaceuticals quick facts

Market cap
$9.93B
P/E ratio
—
Forward P/E
61.4
EPS, TTM
−$5.85
Revenue, TTM
$1.43B
Profit margin
-10.9%
Dividend yield
—
Beta
-1.00
Volume
441,240 avg 582,244
1-year return
−19.2%
Typical daily move
±5.9%
Typical 20-day move
±9.4%
50-day average
$475.72
200-day average
$496.00
Next earnings
Feb 18 before open
Shares outstanding
23.23M
52-week range
$353.54$615.00

Madrigal Pharmaceuticals swing-trade checklist

Madrigal Pharmaceuticals scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed1 headwind

  • Trendheadwind

    Below 50 and 200-day

    Close $427.39 is below the 50-day ($475.72) and 200-day ($496.00) averages, and the 50-day is below the 200-day.

    See the chart
  • GekkoIndexsupportive

    64.8, Accumulation

    Reading 64.8 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    47.4% below

    Price is 47.4% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneymixed

    Mixed

    Last 90 days: 5 open-market insider purchases. Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 95 days

    Next report Feb 18, 2027, 95 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    +3.0% on average

    From this point in the calendar, the next 20 trading days averaged +3% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Madrigal Pharmaceuticals stock chart and price history

Madrigal Pharmaceuticals closed at $427.39 on Nov 13, 2026, −19.2% over the past year, inside a 52-week range of $353.54 to $615.00.

Close50-day average200-day averageVolume
Madrigal Pharmaceuticals share price, past year, with 50-day and 200-day moving averages and volume$350$400$450$500$550$600DecJan 2026FebMarAprMayJunJulAugSepOctNov427.39

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−7.1%
3 months
−18.6%
6 months
−18.4%
1 year
−19.2%
The full MDGL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MDGL in Gekko

Follow Madrigal Pharmaceuticals through every session

Put MDGL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track MDGL in GekkoFree for 7 days. No credit card required.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals works on new medicines for conditions tied to the heart, metabolism, and liver, with a focus on drugs still moving through clinical testing rather than products already on the market. Its furthest-along candidate, resmetirom, targets the liver and works on a specific thyroid hormone receptor, and it is being studied in late-stage Phase III trials for treating non-alcoholic steatohepatitis, a liver disease often referred to as NASH.

Behind resmetirom sits a second compound, MGL-3745, kept in reserve in case it is needed to support or replace the lead candidate. Madrigal also has a partnership with Hoffmann-La Roche that spans research, development, and eventual commercialization work, linking its drug programs to a larger collaborator as they progress.

The company operates out of West Conshohocken, Pennsylvania, and its shares are listed on the NASDAQ under the ticker MDGL.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
madrigalpharma.com

Madrigal Pharmaceuticals GekkoIndex: the smart money zone

Madrigal Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.8, in the Accumulation zone, down 16.8 points over five sessions.

010064.8Accumulation

Down 16.8 points over five sessions, from the Buying zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying47+2.3%+2.7%+8.8%+19.4%
Accumulation (current zone)245+0.7%+2.5%+6.6%+16.5%
Neutral356+0.3%+0.4%+0.1%+1.8%
Distribution48+2.3%+3.8%+4.4%+0.3%
Selling6Too few readings yet

Average MDGL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the MDGL price, zone by zone.Track MDGL in Gekko

Is Madrigal Pharmaceuticals stock overvalued? Gekko Fair Value

Madrigal Pharmaceuticals trades 47.4% below Gekko Fair Value of $813.11, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Madrigal Pharmaceuticals shares are worth, recalculated every trading day.

$813.11

Gekko Fair Value, Nov 14, 2026

47.4% Undervalued

At the end of Aug 2026 the price was 13.6% below the estimate.

Gekko Fair ValueShare price, month end
$813$427Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open MDGL in Gekko

Madrigal Pharmaceuticals insider and Congress trading

Insiders filed 5 open-market purchases in Madrigal Pharmaceuticals worth $35.02M, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

$35.02Min 5 open-market purchases

FiledInsiderTypeSharesValue
Nov 6BAKER BROS. ADVISORS LP
director
Purchase60,400$23.13M
Nov 6BAKER BROS. ADVISORS LP
director
Purchase13,740$5.34M
Nov 6BAKER BROS. ADVISORS LP
director
Purchase10,080$3.71M
Nov 6BAKER BROS. ADVISORS LP
director
Purchase5,586$2.05M
Nov 6BAKER BROS. ADVISORS LP
director
Purchase2,000$793K

From Form 4 filings, dated to when each was filed.

Congress trades last 90 days

No trades in MDGL were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for MDGL, plotted on the chart in Gekko.Open MDGL in Gekko

Unusual options activity last 30 days

1signal, 37% of the flagged premium in calls.

Latest: Bullish flow on Oct 17, $1.06M in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds MDGL.

0added0opened1trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Madrigal Pharmaceuticals earnings: next date and track record

Madrigal Pharmaceuticals reports on Feb 18, 2027, before the open (95 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±9.7%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+8.5%Feb ’25−5.5%May ’25+8.3%Aug ’25+15.4%Nov ’25−11.5%Feb ’26+6.4%May ’26−14.5%Jul ’26−7.1%Nov ’26

Last earnings call, Nov 3, 2026 AI summary

What they said
Madrigal Pharmaceuticals reported Q3 2026 net sales of $431 million, up 50% year-over-year, crossing $1 billion in year-to-date sales and annualizing at over $1.7 billion. Active Rezdiffra patients reached 55,850, nearly double the 29,500 from a year ago. The diagnosed U.S. F2/F3 MASH market expanded to 530,000+ patients, growing 30%+ in 2026. The company is advancing F4c trials including MAESTRO-NASH OUTCOMES and new MAESTRO-CSPH Phase III.
Guidance
Management expects the MASH market to grow over 30% by end of 2026, with Rezdiffra targeting mega-blockbuster status. Patent protection extends to 2045, and F4c program aims to be first approved therapy in that indication.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 3, 2026$1.83
est −$0.86
+312.0%$431.3M
est $404.2M
+6.7%−7.1%
Jul 30, 2026−$1.99
est −$2.55
+22.0%$364.3M
est $352.1M
+3.5%−14.5%
May 6, 2026−$1.38
est −$4.14
+66.7%$311.3M
est $301.1M
+3.4%+6.4%
Feb 19, 2026−$2.57
est $0.04
−6,525.0%$321.1M
est $312.5M
+2.8%−11.5%
Nov 4, 2025−$4.96
est −$1.99
−149.2%$287.3M
est $245.0M
+17.3%+15.4%
Aug 5, 2025−$1.90
est −$3.48
+45.4%$212.8M
est $243.5M
−12.6%+8.3%
May 1, 2025−$3.32
est −$3.79
+12.4%$137.3M
est $158.9M
−13.6%−5.5%
Feb 26, 2025−$2.71
est −$4.12
+34.3%$103.3M
est $97.81M
+5.6%+8.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Madrigal Pharmaceuticals stock forecast and analyst price targets

Analysts’ average 12-month price target for Madrigal Pharmaceuticals is $688.78, +61.2% from the last close, from 10 firms rating the stock in the last 90 days.

$688.78consensus 12-month target, +61.2% from the last close
Low $479High $962
Buy9
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 10 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 12H.C. WainwrightBuy, reiterated$620+45.1%
Nov 9Bank of America SecuritiesHold, maintained$479+12.1%
Nov 4CitiBuy, maintained$760+77.8%
Nov 4Bank of America SecuritiesHold, reiterated$479+12.1%
Nov 4BarclaysBuy, maintained$962+125.1%
+6.6%average 20-day move after past Accumulation readings
+3.0%average move over the next 20 trading days in the last 5 years
±5.9%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Madrigal Pharmaceuticals seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Madrigal Pharmaceuticals averaged +3.0% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−19.9%2021−12.5%2022+45.3%2023+0.6%2024+5.9%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+1.4%3 of 5
Next 10 trading days+5.7%3 of 5
Next 15 trading days+7.6%2 of 5
Next 20 trading days+3.0%2 of 5
Next 30 trading days+65.9%3 of 5

For scale, MDGL’s typical 20-trading-day move in either direction is about 9.4%.

Madrigal Pharmaceuticals market cap and key statistics

Madrigal Pharmaceuticals’s market cap is $9.93B and revenue of $1.43B over the last twelve months.

Valuation

Market cap
$9.93B
Forward P/E
61.4
EPS, TTM
−$5.85
Gekko Fair Value
$813.11

Trading

Volume
441,240
Avg volume, 20 days
582,244
52-week high
$615.00
52-week low
$353.54
Shares outstanding
23.23M

Financials

Revenue, TTM
$1.43B
Profit margin
-10.9%
Return on equity
-24.8%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
-1.00
Typical daily move
±5.9%
Typical 20-day move
±9.4%

Madrigal Pharmaceuticals peers

Madrigal Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Madrigal Pharmaceuticals stock FAQ

What is Madrigal Pharmaceuticals’s market cap?

Madrigal Pharmaceuticals’s market cap is $9.93B at the Nov 13, 2026 close of $427.39, with 23.23M shares outstanding.

What is the Madrigal Pharmaceuticals stock forecast?

The consensus analyst 12-month price target for Madrigal Pharmaceuticals is $688.78, +61.2% from the last close. Of the 10 firms that rated the stock in the last 90 days, 9 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Madrigal Pharmaceuticals stock overvalued or undervalued?

On Gekko’s estimate Madrigal Pharmaceuticals is undervalued: the Nov 13, 2026 close of $427.39 is 47.4% below Gekko Fair Value of $813.11. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Madrigal Pharmaceuticals report earnings next?

Madrigal Pharmaceuticals is expected to report on Feb 18, 2027, before the market opens (95 days away). Analysts expect earnings of $1.43 per share on revenue of $477.0M. Madrigal Pharmaceuticals beat the earnings estimate in 6 of its last 8 reports, moving 9.7% on average across the report.

What is Madrigal Pharmaceuticals’s 52-week high and low?

Madrigal Pharmaceuticals’s 52-week high is $615.00 and its 52-week low is $353.54; it closed at $427.39 on Nov 13, 2026, −19.2% over the past year.

Is Madrigal Pharmaceuticals stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, fair value and earnings risk), 2 as mixed (smart money and seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Madrigal Pharmaceuticals?

Gekko flagged 1 unusual options signal in Madrigal Pharmaceuticals over the last 30 days, with $398K of flagged premium in calls and $667K in puts. The latest, bullish flow, was on Oct 17, 2026 with $1.06M in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Madrigal Pharmaceuticals the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.